Although CpG did not enhance PD-L1 blockade in the subcutaneous (s.c.)administration setting we used, intratumorally provided CpG may synergize with blockade of the PD-1-PD-L1 pathway66 by enhancing dendritic-cell-mediated cross-presentation of tumor antigens.67 The gene discussed is CD274; the disease is neoplasm.